DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

MM de Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - ingentaconnect.com
Background: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …
被引用次数：8 相关文章

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

MM de Souza, AR Cenci, KF Teixeira… - Current medicinal …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease.

MM de Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - europepmc.org
Background Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …
[PDF] researchgate.net

[PDF][PDF] DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's

MM de Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - researchgate.net
Background: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …

[引用][C] DYRK1A inhibitors and perspectives for the treatment of alzheimer's disease

MM Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - repositorio.usp.br
ReP USP - Detalhe do registro: DYRK1A inhibitors and perspectives for the treatment of
alzheimer's disease Home About USP Schools USP Schools Escola de Artes, Ciências e …